Quest Diagnostics 2007 Annual Report Download - page 101

Download and view the complete annual report

Please find page 101 of the 2007 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

projected performance and reduced the number of performance share units by 0.1 million and 0.6 million,
respectively.
As of December 31, 2007, there was $15 million of unrecognized stock-based compensation cost related to
nonvested stock awards, which is expected to be recognized over a weighted average period of 1.8 years. Total
fair value of shares vested was $3.8 million, $2.1 million and less than $0.1 million for the year ended December
31, 2007, 2006 and 2005, respectively. The amount of unrecognized stock-based compensation cost is subject to
change based on revisions, if any, to management’s best estimates of the achievement of the performance goals
specified in such awards and the resulting number of shares that will be earned at the end of the performance
periods.
For the years ended December 31, 2007, 2006 and 2005, stock-based compensation expense totaled $57
million, $55 million and $2.0 million, respectively. Income tax benefits related to stock-based compensation
expense totaled $23 million and $22 million for the year ended December 31, 2007 and 2006, respectively.
Income tax benefits related to stock-based compensation for 2005 were not material.
Employee Stock Purchase Plan
Under the Company’s Employee Stock Purchase Plan (“ESPP”), which was approved by the Company’s
shareholders at the 2006 Annual Meeting of Shareholders, substantially all employees can elect to have up to
10% of their annual wages withheld to purchase Quest Diagnostics common stock. The purchase price of the
stock is 85% of the market price of the Company’s common stock on the last business day of each calendar
month. Under the ESPP, the maximum number of shares of Quest Diagnostics common stock which may be
purchased by eligible employees is 5 million. Approximately 448, 474 and 409 thousand shares of common stock
were purchased by eligible employees in 2007, 2006 and 2005, respectively.
Defined Contribution Plans
The Company maintains qualified defined contribution plans covering substantially all of its employees, and
matches employee contributions up to a maximum of 6%. The Company’s expense for contributions to its
defined contribution plans aggregated $76 million, $69 million and $64 million for 2007, 2006 and 2005,
respectively.
Supplemental Deferred Compensation Plan
The Company’s supplemental deferred compensation plan is an unfunded, non-qualified plan that provides
for certain management and highly compensated employees to defer up to 50% of their eligible compensation in
excess of their defined contribution plan limits. In addition, certain members of senior management have an
additional opportunity to defer up to 95% of their variable incentive compensation. The compensation deferred
under this plan, together with Company matching amounts, are credited with earnings or losses measured by the
mirrored rate of return on investments elected by plan participants. Each plan participant is fully vested in all
deferred compensation, Company match and earnings credited to their account. Although the Company is
currently contributing all participant deferrals and matching amounts to a trust, the funds in the trust, totaling $34
million and $30 million at December 31, 2007 and 2006, respectively, are general assets of the Company and are
subject to any claims of the Company’s creditors. The Company’s expense for matching contributions to this plan
were approximately $1 million for 2007, 2006 and 2005.
14. RELATED PARTY TRANSACTIONS
At December 31, 2007, GlaxoSmithKline plc (“GSK”), the result of the merger of Glaxo Wellcome and
SmithKline Beecham in December 2000, beneficially owned approximately 19% of the outstanding shares of
Quest Diagnostics common stock.
Quest Diagnostics is the primary provider of testing to support GSK’s clinical trials testing requirements
worldwide (as amended, the “Clinical Trials Agreements”). Net revenues, primarily derived under the Clinical
Trials Agreements were $79 million, $87 million and $69 million for 2007, 2006 and 2005, respectively.
F-31
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(dollars in thousands unless otherwise indicated)